[February 25, 2014]

OncoSec Medical to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference

OncoSec Medical Inc. (OTCQB: ONCS), a company developing its advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid tumors, today announced that Punit Dhillon, President and CEO, will present a corporate overview of the company at the 24th Annual Wall Street Analyst Forum Institutional Investor Conference at the University Club in New York, New York on Monday, March 3rd at 12:05 p.m. (EST).

At the time of the presentation, a live webcast of OncoSec's presentation will be available at the following link: http://www.visualwebcaster.com/event.asp?id=98095

OncoSec recommends registering at least 10 minutes prior to the start of the presentation to ensure timely access. Participants will require Windows Media Player (a free download is available from the presentation link) in order to participate. After the presentation, an archived version of the webcast will be available on OncoSec's web page at http://www.ncosec.com under the "Events" tab.

About the Wall Street Analyst Forum Institutional Investor Conference

Since 1989, the Wall Street Analyst Forum has conducted over 80 multiday/multitrack analyst conferences in Boston, New York, and London; in which over 2500 different NYSE/NASDAQ/AMEX/OTC companies have presented, and over 2000 different institutions have attended. Analysts and portfolio managers from the vast majority of money management firms attend its conferences either in person or via webcast, and past presenters have included such companies as General Electric, Pfizer, Microsoft (News - Alert) Corp, and Mattel. In 1998, WSAF received extensive coverage in the financial press for conducting the first live webcast of individual corporate meetings from an investor conference. The 24^th Annual Institutional Investor Conference will take place March 3-4, 2014 at the University Club in New York City.

About OncoSec Medical Inc.

OncoSec Medical Inc. is a biopharmaceutical company developing its advanced-stage ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core technology leverages a proprietary electroporation platform to enhance the local delivery and uptake of IL-12 and other DNA-based immunocytokines. Clinical studies of ImmunoPulse have demonstrated positive safety and preliminary efficacy in the treatment of various skin cancers, as well as its potential to initiate a systemic immune response without the toxicities associated with other systemic treatments. OncoSec's clinical programs currently include three Phase 2 clinical trials targeting metastatic melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma. As the company continues to evaluate ImmunoPulse in these indications, it is also investigating additional indications as well as efficacious combination approaches. For more information, please visit www.oncosec.com.

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward-looking statements." Forward-looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties, which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition, and market conditions. These and additional risks and uncertainties are more fully described in OncoSec Medical's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made. OncoSec Medical disclaims any obligation to update any forward-looking statements to reflect new information, events or circumstances after the date they are made, or to reflect the occurrence of unanticipated events.

[ Back To TMCnet.com's Homepage ]